A Phase I/II Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Mitoxantrone liposomal (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 22 Feb 2024 Status changed from not yet recruiting to discontinued.
- 29 Apr 2022 New trial record